Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.73 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.68 |
| ▸ | FBP1 | P09467 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | FLT4 | P35916 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.65 |
| ▸ | CD38 | P28907 | 1/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 1/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299934 | 1.00 | EGFR (1.00) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL29923578 | 1.00 | EGFR (1.00) | EGFRGRM1ERBB2FBP1AURKA | |
| Hydrochloric Acid SCHEMBL7764930 | 0.99 | EGFR (0.97) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL6186070 | 0.87 | EGFR (0.77) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL6188729 | 0.87 | EGFR (0.77) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL8311292 | 0.87 | EGFR (0.77) | EGFRGRM1ERBB2FBP1AURKA | |
| Hydrochloric Acid SCHEMBL7760887 | 0.86 | EGFR (0.76) | EGFRGRM1ERBB2 | |
| SCHEMBL21083167 | 0.86 | EGFR (0.75) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL641359 | 0.86 | EGFR (0.75) | EGFRGRM1ERBB2FBP1AURKA | |
| SCHEMBL1734677 | 0.86 | EGFR (0.75) | EGFRGRM1ERBB2FBP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| WO-2006071079-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | claimed |
| EP-0824526-B1 | QUINAZOLINE DERIVATIVE | ASTRAZENECA AB (SE) | 2001-06-13 | — | — | EP | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-115073439-B | Pyrimidine compound and medical application thereof | 徐州医科大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-115073439-A | Pyrimidine compound and medical application thereof | 徐州医科大学 | 2022-09-20 | — | — | CN | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996033979-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996033978-A1 | QUINAZOLINE DERIVATIVE | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 1400/4885GRM1 4203/4885ERBB2 1693/4885 |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885GRM1 3316/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.